The levonorgestrel‐releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis

Yucel N, Neşe Yücel, Nese Yucel, Baskent E, Erdem Baskent, Erdem Başkent, Burçin Karamustafaoğlu Balcı, Gökhan Göynümer, Gokhan Goynumer
The Australian & New Zealand journal of obstetrics & gynaecology · 2018 · vol. 58(5) , pp. 560–563 · doi:10.1111/ajo.12773 · PMID:29359457 · W2789506724
article OA: green CC0 ⤵ 20 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Levonorgestrel-releasing intrauterine systems reduced dysmenorrhoea, dyspareunia, CA 125 levels, and endometrioma size while improving quality of life in women with suspected endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-14 · read from full text ⓘ

This 2-year study evaluated the effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) for symptomatic pain relief in 45 women with suspected endometriosis, with repeated assessments of dysmenorrhoea, dyspareunia, quality of life (Short Form-36), and serum CA 125 measured at baseline and multiple follow-up visits up to 12 months. After 12 months, mean dysmenorrhoea and dyspareunia VAS scores decreased substantially, CA 125 levels decreased from about 50.7 to 22.5, and in some participants endometriomas reduced in size or disappeared. The paper notes that a few women experienced typical systemic progestogen-related adverse effects, though LNG-IUS-related adverse events were generally tolerable and discontinuation was low (6.66%). This paper is centrally about endometriosis—specifically, LNG-IUS–associated reductions in pain, endometrioma size, and CA 125 in women with suspected endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND AND AIMS: The aim of this study was to investigate the effectiveness of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic relief of pain in women with endometriosis and additionally, to assess the changes in women's life quality and serum cancer antigen (CA) 125 levels. MATERIALS AND METHODS: All women who had an LNG-IUS inserted for the treatment of dysmenorrhea, chronic pelvic pain or both for more than six months over a two-year period were included in the study. Each woman was asked to complete questionnaires of the Short Form-36 and visual analogue scales (VAS) in the first visit and the third, sixth, ninth and twelfth months after the LNG-IUS insertion. CA 125 levels were measured at each visit. RESULTS: Forty-five women were included in the study. At the end of 12 months, mean dysmenorrhoea VAS score decreased from 6.13 to 2.88, mean dsyspareunia VAS score from 6.04 to 2.61 and CA 125 level from 50.67 to 22.45. Endometriomas reduced in size in six women (mean size decreased from 31 to 20 mm) and disappeared in three. CONCLUSIONS: Several favourable outcomes were found following LNG-IUS insertion: (i) dyspareunia and dysmenorrhoea were clearly reduced; (ii) the size of endometriomas were decreased; (iii) CA 125 levels significantly decreased; (iv) a few women experienced the typical systemic adverse effects of progestogens; however, LNG-IUS-related adverse events were generally tolerable and the discontinuation rate was as low as 6.66% (3/45).
Full text 2,232 characters · extracted from oa-html · click to expand
The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis Yükleniyor... Dosyalar Tarih 2018 Dergi Başlığı Dergi ISSN Cilt Başlığı Yayıncı Wiley Erişim Hakkı info:eu-repo/semantics/closedAccess Özet Background and aimsThe aim of this study was to investigate the effectiveness of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic relief of pain in women with endometriosis and additionally, to assess the changes in women's life quality and serum cancer antigen (CA) 125 levels. Materials and methodsAll women who had an LNG-IUS inserted for the treatment of dysmenorrhea, chronic pelvic pain or both for more than six months over a two-year period were included in the study. Each woman was asked to complete questionnaires of the Short Form-36 and visual analogue scales (VAS) in the first visit and the third, sixth, ninth and twelfth months after the LNG-IUS insertion. CA 125 levels were measured at each visit. ResultsForty-five women were included in the study. At the end of 12months, mean dysmenorrhoea VAS score decreased from 6.13 to 2.88, mean dsyspareunia VAS score from 6.04 to 2.61 and CA 125 level from 50.67 to 22.45. Endometriomas reduced in size in six women (mean size decreased from 31 to 20mm) and disappeared in three. ConclusionsSeveral favourable outcomes were found following LNG-IUS insertion: (i) dyspareunia and dysmenorrhoea were clearly reduced; (ii) the size of endometriomas were decreased; (iii) CA 125 levels significantly decreased; (iv) a few women experienced the typical systemic adverse effects of progestogens; however, LNG-IUS-related adverse events were generally tolerable and the discontinuation rate was as low as 6.66% (3/45). Açıklama Balci, Burcin Karamustafaoglu/0000-0001-5196-4502 WOS: 000446978700018 PubMed: 29359457 WOS: 000446978700018 PubMed: 29359457 Anahtar Kelimeler CA 125, contraception, endometriosis, levonorgestrel-releasing intrauterine device, life quality, Mirena Kaynak Australian & New Zealand Journal Of Obstetrics & Gynaecology WoS Q Değeri Q3 Scopus Q Değeri Q2 Cilt 58 Sayı 5

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

dysmenorrheadyspareuniaendometriosischronic_pelvic_pain

MeSH descriptors

Contraceptive Agents, Female Dysmenorrhea Endometriosis Intrauterine Devices, Medicated Levonorgestrel Pelvic Pain Adult CA-125 Antigen CA-125 Antigen Chronic Pain Chronic Pain Chronic Pain Contraceptive Agents, Female Contraceptive Agents, Female Cross-Sectional Studies Dysmenorrhea Dysmenorrhea Dyspareunia Dyspareunia Dyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Cited by (20)

Source provenance

europepmc
last seen: 2026-09-20T09:27:46.357103+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:01.354358+00:00
License: CC0 · commercial use OK